Filing Flows › Viridian Therapeutics (VRDN) › Q1 2025
Viridian Therapeutics (VRDN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Viridian Therapeutics (VRDN) reported revenue of $72K for the first quarter 2025 (Q1 2025), 0% from a year earlier and 0% from the quarter before.
Viridian Therapeutics, Q1 2025: revenue $72K (0% year over year), net loss $86.9M, operating cash flow −$92.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $72K | 0% | 0% |
| Operating profit | −$93.9M | — | — |
| Net earnings | −$86.9M | — | — |
| Operating cash flow | −$92.7M | — | — |
What changed
Revenue was $72K in Q1 2025, roughly flat year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $93.9M, an operating margin of -130369.4%. Total costs grew 68% against flat revenue. The fastest-growing cost line was Research & development (+88%). The quarter ended with a net loss of $86.9M, wider than the previous quarter's $79.7M loss.
Operating cash flow was −$92.7M. Non-cash charges added back $117K of depreciation and amortization and $10.2M of share-based compensation. Working capital and other items used $16.1M. Capital expenditures of $86K exceeded it, leaving free cash flow of −$92.7M.
Questions
What was Viridian Therapeutics' revenue in the first quarter 2025?
Viridian Therapeutics (VRDN) reported revenue of $72K for the first quarter 2025 (Q1 2025), 0% from a year earlier and 0% from the quarter before.